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Abstract
Background: Despite the wide spread use of lumefantrine, there is no study reporting the detailed preclinical
pharmacokinetics of lumefantrine. For the development of newer anti-malarial combination(s) and selection of
better partner drugs, it is long felt need to understand the detailed preclinical pharmacokinetics of lumefantrine in
preclinical experimental animal species. The focus of present study is to report bioavailability, pharmacokinetics,
dose linearity and permeability of lumefantrine in rats.
Methods: A single dose of 10, 20 or 40 mg/kg of lumefantrine was given orally to male rats (N = 5 per dose level)
to evaluate dose proportionality. In another study, a single intravenous bolus dose of lumefantrine was given to
rats (N = 4) at 0.5 mg/kg dose following administration through the lateral tail vein in order to obtain the absolute
oral bioavailability and clearance parameters. Blood samples were drawn at predetermined intervals and the
concentration of lumefantrine and its metabolite desbutyl-lumefantrine in plasma were determined by partially
validated LC-MS/MS method. In-situ permeability study was carried in anaesthetized rats. The concentration of
lumefantrine in permeability samples was determined using RP-HPLC.
Results: For nominal doses increasing in a 1:2:4 proportion, the Cmax and AUC0-∞ values increased in the
proportions of 1:0.6:1.5 and 1:0.8:1.8, respectively. For lumefantrine nominal doses increasing in a 1:2:4 proportion,
the Cmax and the AUC0-t values for desbutyl-lumefantrine increased in the proportions of 1:1.45:2.57 and 1:1.08:1.87,
respectively. After intravenous administration the clearance (Cl) and volume of distribution (Vd) of lumefantrine in
rats were 0.03 (± 0.02) L/h/kg and 2.40 (± 0.67) L/kg, respectively. Absolute oral bioavailability of lumefantrine
across the tested doses ranged between 4.97% and 11.98%. Lumefantrine showed high permeability (4.37 × 10
-5
cm/s) in permeability study.
Conclusions: The pharmacokinetic parameters of lumefantrine and its metabolite desbutyl-lumefantrine were
successfully determined in rats for the first time. Lumefantrine displayed similar pharmacokinetics in the rat as in
humans, with multiphasic disposition, low clearance, and a large volume of distribution resulting in a long terminal
elimination half-life. The absolute oral bioavailability of lumefantrine was found to be dose dependent.
Lumefantrine displayed high permeability in the in-situ permeability study.
Background
According to the World Health Organization (WHO),
there were in 2008 an estimated 247 million malaria
cases among more than 3 billion people at risk, causing
nearly one million deaths (even much more according
to other estimates), mostly of children under 5 years
and pregnant women [1]. The burden of malaria disease
continues to increase as the countries in which it is
endemic face the risk of widespread resistance of the
parasite to conventional anti-malarial drugs and increas-
ing resistance of the vector to insecticide. Artemether/
lumefantrine (AL; Coartem
®) is an artemisinin-based
combination therapy (ACT) that offers PCR-corrected
28-day cure rates of > 95% [2-9], if given in a six-dose
regimen. AL meets the WHO pre-qualification criteria
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has been approved by ICH stringent regulatory authori-
ties [10].
Despite the potency of artemether, 100-100,000 resi-
dual parasites remain when the drug is used alone for a
three-day treatment course, and as a result up to 10% of
patients experience recrudescence [11,12]. It was recog-
nized that combination treatment, which eliminated the
final parasites, would be advantageous. Lumefantrine,
the other active constituent of AL, acts over a longer
period to eliminate the residual 100-100,000 parasites
that remain after artemether is cleared from the body
and thus minimizes the risk of recrudescence. Arte-
mether and lumefantrine have different modes of action
and act at different points in the parasite life cycle
[13,14]. Artemisinin derivatives, such as artemether,
have multiple mechanisms of action, including interfer-
ence with parasite transport proteins, disruption of para-
site mitochondrial function, modulation of host immune
function and inhibition of angiogenesis [15]; Whereas,
lumefantrine prevents the detoxification of haem, such
that toxic haem and free radicals induce parasite death
[13]. Additionally, the differing pharmacokinetics of the
two agents offers an advantage for combination therapy.
Furthermore, in vitro, artemether and lumefantrine have
shown synergistic action against Plasmodium falciparum
under in vitro conditions [16].
The anti-malarial agent lumefantrine, which was origin-
ally synthesized by the Academy of Military Medical
Sciences in Beijing [17], was identified by researchers at the
Academy as a promising agent for combination with arte-
misinin. Lumefantrine, 2-(dibutylamino)-1-[(9E)-2,7-
dichloro-9-[(4-chlorophenyl) methylidene] fluoren-4-yl]
ethanol is an arylamino alcohol [14]. Its molecular weight
is 528.939 g/mol. It is a lipophillic compound with low
intrinsic clearance and erratic oral variability and therapeu-
tic levels are more reliably achieved by co-administration
with a fatty meal [14,18-22]. Lumefantrine is eliminated
very slowly with a terminal half-life of 2-3 days in healthy
volunteers and 4-6 days in patients with falciparum malaria
[14,18,23,24]. Its plasma protein binding is almost 100%
[25]. Lumefantrine is predominantly, metabolized by cyto-
chrome P450 3A4 (CYP3A4), to desbutyl lumefantrine
(DLF). The in vitro antiparasitic effect of desbutyl- lume-
fantrine is 5 to 8 fold higher than lumefantrine [26].
Recently, Wong et al [27] reported that DBL has
potential as an anti-malarial drug in its own right. Its in
vitro potency relative to that of the parent compound
(lumefantrine), its synergy with dihydroartemisinin and
the positive relationship between day 7 plasma concen-
trations and adequate clinical and parasitological
response (ACPR) suggest that it could be a useful alter-
native to lumefantrine as a part of artemisinin-based
combination therapy (ACT).
The limitation of artemether-lumefantrine combina-
tion is the side effects associated with artemether, i.e
hearing impairment, its high cost, and its variable
absorption and the strong food effect on the pharmaco-
kinetics of lumefantrine. Development of newer anti-
malarial combinations require detailed preclinical phar-
macokinetic assessment of combination partner drugs
separately as well as in combination for better under-
standing of their efficacy, toxicity and safety profile
before going in to clinical studies. Preclinical pharmaco-
kinetic information is also very useful in dose/dosage
regimen selection of combination partner drugs for clin-
ical assessment. For the development of newer anti-
malarial combination(s) and selection of better partner
drugs, it is long felt need to understand the detailed pre-
clinical pharmacokinetics of existing combination drugs
(viz. lumefantrine, artemether etc.) in preclinical experi-
mental animal species.
All the studies reporting pharmacokinetics of lumefan-
trine dealt with clinical data. Despite the wide spread
clinical use of lumefantrine, there is no study reporting
the detailed preclinical pharmacokinetics. However, the
preclinical pharmacokinetics of artemether in rats has
been reported very recently [28]. The focus of present
study is to report bioavailability, pharmacokinetics, dose
linearity and permeability of lumefantrine. The presence
of preclinical pharmacokinetic data in public domain
will be of immense help in making informed decisions




Lumefantrine, desbutyl-lumefantrine and halofantrine
(IS) were a generous gift from Ipca Laboratories Ltd.
(Mumbai, India). Phenol red and HPLC grade acetoni-
trile were purchased from Sisco Research Laboratories
(SRL) Pvt. Limited (Mumbai, India). HPLC grade n-hex-
ane was obtained from E Merck Limited (Mumbai,
India). HPLC grade methanol was purchased from Tho-
mas Baker Pvt. Limited (Mumbai, India). Ammonium
acetate, ethanol and glacial acetic acid (GAA) AR were
purchased from E Merck Limited (Mumbai, India).
Potassium dihydrogen orthophosphate was purchased
from New India Chemical Enterprises (Cochin, India).
Polyethylene glycol (PEG400) and Carboxy methyl cellu-
lose (CMC) were purchased from Sigma Aldrich Ltd (St
Louis, USA). Dimethylformamide was purchased from
Thomas Baker (chemicals) Pvt. Limited (Mumbai,
India). Urethane was purchased from Thermo Fisher
Scientific India Pvt. Ltd. (Mumbai, India). Ultra pure
water was obtained from a Sartorious Arium 611 sys-
tem. Heparin sodium injection I.P. (1000 IU/mL, Biolo-
gicals E. Limited, Hyderabad, India) was purchased from
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Page 2 of 9local pharmacy. Blank, drug free plasma samples were
collected from adult, healthy male Sprague-Dawley (SD)
rats at the Division of Laboratory Animals (DOLA) of
Central Drug Research Institute (Lucknow, India).
Plasma was obtained by centrifuging the heparinized
blood (25 IU/mL) at 2000 × g for 10 min at 20°C. Prior
approval from the Institutional Animal Ethics Commit-
tee (IAEC) was sought for maintenance, experimental
studies, euthanasia and disposal of carcass of animals.
Animals
Young, adult male SD rats, weighing 200-220 g, were
procured from the National Laboratory Animal Center,
CDRI (Lucknow, India). Rats were housed in well venti-
lated cages at room temperature (24 ± 2°C) and 40-60%
relative humidity while on a regular 12 h light-dark
cycle. The animals were acclimatized for a minimum
period of three days prior to the experiment. Approval
from the Institutional Animal Ethics Committee was
sought and the study protocols were approved before
the commencement of the studies.
In-situ permeability studies
Single-pass intestinal perfusion studies in rats were per-
formed using established methods adapted from the lit-
erature [29]. Briefly, male SD rats were fasted overnight
for 12 to 16 h with free access to water and anaesthe-
tized using an intra-peritoneal injection of urethane (1
g/kg) and placed on a heated pad to keep normal body
temperature. Upon verification of the loss of pain reflex,
a midline longitudinal abdominal incision was made,
and the lumen of the jejunum (10 cm) was flushed with
10 ml of saline pre-warmed to 37°C. The proximal end
of the lumen was catheterized with an inlet polypropy-
lene tube, which was connected to a perfusion pump.
The distal end of the jejunum was also catheterized with
an outlet polypropylene tube to collect intestinal efflu-
ent. Care was taken to handle the small intestine gently
and to minimize the surgery in order to maintain an
intact blood supply. The entire excised area was covered
with an absorbable cotton pad soaked in warmed nor-
mal saline. After allowing 30 min to reach steady-state
outlet concentrations, outlet perfusate samples were col-
lected every 15 min for 120 min perfusion period. Phe-
nol red was used as a marker of osmosis/zero
permeability. At the end, the length of segment was
measured without stretching and finally the animal was
euthanized. Samples were stored at -20°C until analysis.
HPLC analysis of In-situ permeability samples
The concentration of lumefantrine and phenol red in
permeability samples was determined by high-perfor-
mance liquid chromatography (HPLC) coupled with
PDA detector. Chromatographic separation was
performed on a Supelco Discovery C18 column (4.6 ×
150 mm, 5.0 μm). Mobile phases were duly filtered
through 0.22 μm Millipore filter (Billerica, USA) and
degassed ultrasonically for 15 min and then were
pumped in gradient mode. The detail of the gradient
program is given in Table 1. The lumefantrine and phe-
nol red were detected at the wavelength of 235 and 420
nm, respectively.
Permeability data analysis
The single pass intestinal perfusion is based on reaching
steady state with respect to the diffusion of compound
across intestine. Steady state is confirmed by plotting the
ratio of the outlet to inlet concentrations (corrected for
water transport) versus time. The outlet concentrations
were corrected by multiplying the inlet concentration with
[phenol red]in /[phenol red]out. Permeability calculations
across rat jejunum (Peff) were performed from intestinal
perfusate samples collected over 30-120 min (steady state).
[phenol red]in and [phenol red]out are the inlet and
outlet concentrations of the water flux marker phenol
red. The effective permeability coefficient (Peff) and drug




















Where, Cout is the corrected concentration of the per-
meant in the exiting perfusate; Cin is the concentration
of the permeant in entering perfusate; Qin is the flow
rate of entering perfusate (0.2 mL/min); r is the inner
radius of the intestine, which is 0.18 cm [30]; and l is
the length of the intestine.
Pharmacokinetic studies
Dose proportional oral pharmacokinetic studies
Male SD rats weighing 200-220 g were fasted overnight
(12-14 h) before dosing and had free access to water
Table 1 HPLC gradient used for the determination of




Solvent A Solvent B Flow rate
(mL/min)
0-4 6 5 3 5 1
4 - 12 30 70
12 - 17 65 35
Solvent A: KH2PO4 buffer (10 mM, pH-3)
Solvent B: Methanol
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Page 3 of 9throughout the experimental period. Lumefantrine in
0.25% CMC suspension was administered orally at a
dose of 10, 20 & 40 mg/kg to groups of five rats at each
dose level. Animals were provided with standard diet 3
h after dosing. The rats were anaesthetized using ether
and blood samples (approximately 0.25 mL) were col-
lected from the retro-orbital plexus into heparinized
microfuge tubes at 0.5, 2, 5, 8, 24, 30, 48, 54, 72 and
120 h post-dosing. Plasma was harvested by centrifuging
the blood at 13000 rpm for 10 min on Sigma 1-15 K
(Frankfurt, Germany) and stored frozen at -70 ± 10°C
until bioanalysis.
Intravenous pharmacokinetic study
Another group of male SD rats (N = 4) weighing 200-
220 g, were used in this part of the study. The intrave-
nous formulation was prepared in DMF-PEG 400-etha-
nol-water (5: 2.5: 1: 1.5 v/v) and finally filtered through
0.22 μm filter before administration. The solution of
lumefantrine was administered to rats via a lateral tail
vein as a bolus dose of 0.5 mg/kg. Animals had free
access to food and water throughout the experimenta-
tion period. Blood samples (approximately 0.25 mL)
were collected from the retro-orbital plexus into hepari-
nized microfuge tubes at 0.08, 0.5, 2, 4, 6, 25, 30, 48, 54,
72, 96 and 120 h post-dosing and plasma was harvested
by centrifuging the blood at 13000 rpm for 10 min and
stored frozen at -70 ± 10°C until bioanalysis.
Sample preparation
A simple liquid-liquid extraction method was followed
for extraction of lumefantrine and desbutyl-lumefantrine
from rat plasma. To 100 μLo fp l a s m ai nat u b e ,1 0μL
of IS solution (halofantrine at 1 μg/mL in methanol), 50
μL of GAA, 50 μL of phosphate buffer (50 mM, pH 3)
were added and mixed for 15 s on a cyclomixer (Spinix
Tarsons, Kolkata, India). Next a 2 mL aliquot of extrac-
tion solvent, n-hexane was added. The mixture was then
vortexed for 3 min, followed by centrifugation for 5 min
at 2000 × g at 20°C on Sigma 3-16 K (Frankfurt, Ger-
many). The organic layer (1.6 mL) was separated and
evaporated to dryness under vacuum in speedvac con-
centrator (Savant Instrument, Farmingdale, USA). The
residue was reconstituted in 200 μL of the mobile phase
and 10 μL of this solution was subjected to LC-MS/MS
analysis.
LC-MS/MS analysis of lumefantrine and desbutyl-
lumefantrine in study samples
Plasma concentrations of lumefantrine and desbutyl-
lumefantrine were determined using partially validated
LC-MS/MS method that was accurate, precise, specific,
sensitive and reproducible. Analyses were carried out
using a HPLC system consists of Series 200 pumps and
auto sampler with temperature controlled Peltier-tray
(Perkin-Elmer instruments, Norwalk, USA) on a XBridge
RP18 column (4.6 × 50 mm, 5.0 μm). The system was
run in isocratic mode with mobile phase consisting of
acetonitrile: methanol (50:50, v/v) and 0.01 M ammo-
nium acetate (pH 4.5) in the ratio of 95:5 (v/v) at a flow
rate of 0.65 mL/min. Mass spectrometric detection was
performed on an API 4000 mass spectrometer (Applied
Biosystems, MDS Sciex Toronto, Canada) equipped with
an API electrospray ionization (ESI) source. The mass
spectrometer was operated at ESI positive ion mode and
detection of the ions was performed in the multiple
reaction monitoring (MRM) mode, monitoring transi-
tion of m/z 529 precursor ion [M+H]
+ to the m/z 511.3
product ion for lumefantrine, m/z 472.1 precursor ion
[M+H]
+ to the m/z 454.1 product ion for desbutyl
lumefantrine and m/z 502 precursor ion [M+H]
+ to the
m/z 511.3 product ion for IS. Data acquisition and
quantitation were performed using analyst software ver-
sion 1.4.1 (Applied Biosystems, MDS Sciex Toronto,
Canada). The retention times for lumefantrine, desbutyl-
lumefantrine and IS were 4.81, 2.61 and 2.30 min,
respectively. The lower limit of quantification of the
method was 2 ng/mL and linearity in the calibration
curve standards were demonstrated up to an upper limit
of 500 ng/mL. Prior to the analysis of samples, three
concentrations (nominal concentrations of 8, 180 and
400 ng/mL) of quality control (QC) samples were pre-
pared in rat plasma. Along with the study samples, QC
samples (N = 4, at each concentration level) were dis-
tributed among the unknown samples in the analytical
run.
Pharmacokinetic analysis
Plasma data were subjected to non-compartmental phar-
macokinetics analysis using WinNonlin (version 5.1,
Pharsight Corporation, Mountain View, USA). The
observed maximum plasma concentration (Cmax)a n d
the time to reach the maximum plasma concentration
(Tmax) were obtained by visual inspection of the experi-
mental data. The area under the plasma concentration
time curve (AUC0-t) was calculated using linear trape-
zoidal method. The total area under the plasma concen-
tration-time curve from time zero to time infinity
(AUC0-∞) was calculated as the sum of AUC0-t and
Clast/kel, where, Clast represents the last quantifiable
concentration and Kel represents the terminal phase
rate constant. The apparent elimination half-life (t1/2)
was calculated as 0.693/kel and the kel was estimated by
linear regression of the plasma concentrations in the
log-linear terminal phase. Clearance (CL) following i.v.
dosing was calculated as Dose/AUC0-∞.T h ea p p a r e n t
volume of distribution (Vd) was given by the quotient
between CL and elimination rate constant kel following
administration of the intravenous bolus dose.
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calculated using the relationship,
%F=[ A U C (0−∞)oral× Dose(i.v.)/AUC(0−∞)i.v.× Dose(oral)] × 100
Results and discussion
Analytical results
The rat plasma samples generated following oral and
intravenous administration of lumefantrine were ana-
lyzed by the partially validated method along with QC
samples. Linearity, specificity & selectivity, recovery,
matrix effect and accuracy & precision were measured
and used as the parameter to assess the assay perfor-
mance. The peak area ratios of analytes to internal
standard in rat plasma were linear over the concentra-
tion range 2-500 ng/ml for both the analytes. The
choice of the regression methods was determined.
Both lumefantrine and desbutyl-lumefantrine data fit
well with a linear regression model, and weighting of
1/concentration
2. The correlation coefficients of the
standard curves for lumefantrine and desbutyl-lume-
fantrine, ranging from 2 to 500 ng/ml, were all >
0.996. LC-MS/MS analysis of the blank plasma samples
showed no interference with the quantification of
lumefantrine, desbutyl lumefantrine and IS (Figure-1).
The extraction recovery of analytes, was determined by
comparing the peak areas of extracted plasma (pre-
spiked) standard QC samples (N = 6) to those of the
post-spiked standards at equivalent concentrations
[31]. The effect of rat plasma constituents over the
ionization of analytes and IS was determined by com-
paring the responses of the post-extracted plasma stan-
dard QC samples (N = 6) with the response of analytes
from neat standard samples at equivalent concentra-
tions [31]. The recovery and matrix effect testing was
performed at three concentrations QC low, QC med-
ium and QC high concentrations viz., 8, 180, and 400
ng/mL for analytes, whereas the recovery and matrix
effect of the IS were determined at a single concentra-
tion of 50 ng/mL. The extraction recoveries of the
lumefantrine and desbutyl-lumefantrine ranged from
70.45 to 80.12%, and the extraction recovery of the
internal standard was 73.31%. The ion suppression or
enhancement by plasma was less than 12% for the ana-
lytes and IS which demonstrated that the matrix effects
do not cause quantitation bias.
Figure 1 Typical multiple reaction monitoring chromatograms of lumefantrine and desbutyl lumefantrine in rat plasma (A) Rat blank
plasma, (B) drug free plasma spiked with lumefantrine and desbutyl-lumefantrine at LLOQ (2 ng/mL) and halofantrine (IS).
Wahajuddin et al. Malaria Journal 2011, 10:293
http://www.malariajournal.com/content/10/1/293
Page 5 of 9The intra-day assay precision and accuracy were esti-
mated by analyzing six replicates at four different QC
levels, i.e., 2 ng/mL (lower limit of quantitation, LLOQ),
8 (QC low), 180 ng/mL (QC medium) and 400 ng/mL
(QC high). The inter-day assay precision was deter-
mined by analyzing the four levels QC samples on three
different runs. The intra- and inter-day assay precision
ranged from 3.74 to 7.63% and 5.79 to 7.32% (R.S.D. %),
respectively, and intra- and inter-day assay accuracy
were between 95.28 to 105.46% and 96.51 to 105.09%,
respectively for both the analytes. The mean predicted
concentrations of QC samples (distributed among the
unknown samples) were between 89.98-107.56% of the
nominal values.
In-situ permeability study
In-situ perfusion of intestinal segments of rodents (rats
or rabbits) is frequently used to study the permeability
and absorption kinetics of drugs. The Peff values of
lumefantrine was determined as the average of six 15
min sampling periods starting from 30 min after the
initiation of perfusion, when steady-state had been
achieved. Phenol red was used as non-absorbable mar-
ker for correction of water flux. During in-house perme-
ability study of amongst USFDA approved high
permeability markers, metoprolol showed minimum per-
meability in rat jejunum (1.88 × 10
-5 cm/s). Peff value of
lumefantrine was found to be 4.37 × 10
-5 cm/s which is
greater than metoprolol permeability. Therefore, lume-
fantrine can be classified under high permeability class
of BCS (biopharmaceutical classification system).
Pharmacokinetic study
The plasma concentrations of lumefantrine were mea-
surable up to 120 hr after oral and intravenous adminis-
tration. Figure- 2 depicts the mean plasma
concentration-time profiles of lumefantrine following
single oral and intravenous administration to male SD
rats. The mean oral and intravenous pharmacokinetic
parameters for lumefantrine are summarized in Table 2.
The variability in plasma concentrations between-ani-
mals were observed for lumefantrine after oral adminis-
tration. However, the low between-animal variability in
plasma concentrations after intravenous doses suggests
absorption to be critical for between-animal variability
in drug exposure. This is also seen in clinical use with
substantial inter-individual variability in the pharmacoki-
netics of lumefantrine after oral administration [14,18].
The Tmax of lumefantrine after oral administration
was found to be in the range of 2-8 h. The reason for
longer Tmax seems to be the low aqueous solubility of
lumefantrine since, lumefantrine displayed high perme-
ability in the in-situ permeability study. Similarly in
humans the Tmax of lumefantrine occurs later, at
approximately six hours post-dosing in healthy volun-
teers and 3-4 hours in malaria patients [14,18].
For nominal doses increasing in a 1:2:4 proportion,
the Cmax and AUC0-∞ values increased in the propor-
tions of 1:0.63:1.53 and 1:0.83:1.81, respectively. Both
Cmax and AUC0-∞ values of lumefantrine were not
increased proportionally with increment of dose, which
could be due to dissolution-limited absorption at higher
doses due to low solubility of lumefantrine.
Figure 2 Plasma concentration versus time profiles of lumefantrine after oral and intravenous administration in rats (N = 5).A l l
concentrations are on the logarithmic scale.
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administration of lumefantrine dropped to 45% in
approximately 0.05 h. Following intravenous administra-
tion, the t1/2 was found to be 30.92 (± 4.81) h. AUC0-∞,
clearance (CL) and volume of distribution (Vd) of lume-
fantrine following administration of 0.5 mg/kg i.v. were
9529.47 (± 1283.18) ng.h/mL, 0.03 (± 0.02) L/h/kg and
2.40 (± 0.67) L/kg, respectively.
The Vd value (2.40 L/kg) of lumefantrine is greater
than the total blood volume (0.054 L/kg) indicating
extensive extravascular distribution. Furthermore, the
mean hepatic blood flow in rats is approximately 3.22
L/h/kg [32]. Using the haematocrit in rat of 0.48 [32],
this yields a mean hepatic plasma flow of 1.74 L/h/kg.
The CL value for lumefantrine (0.03 L/h/kg) represents
less than 2% of the hepatic plasma flow (1.74 L/h/kg),
indicating that lumefantrine is low extraction com-
pound. Absolute oral bioavailability (% F) of lumefan-
trine across the tested doses ranged between 4.80% and
11.56%. The bioavailability was decreased at higher
doses. This non-linear relationship between dose and
bioavailability is well described for other highly lipophi-
lic drugs, e.g. halofantrine [33]. The variable bioavailabil-
ity of lumefantrine between individual doses was also
observed in humans [18]. The bioavailability of a drug
determines the amount reaching the systemic circulation
and it in turn determines the pharmacological effects.
Hence, preclinical pharmacokinetic data will be of
immense help for deciding the partner drug’sd o s ea n d
concentration(s) required for therapeutic efficacy in
order to keep the drug’s concentration at or above cidal
concentration in order to prevent/delay the drug resis-
tance at sub-cidal level.
The plasma concentrations of desbutyl-lumefantrine
were measurable up to 120 h after oral and up to 96 hr
after intravenous administration. Figure 3 depicts the
mean plasma concentration-time profiles of desbutyl-
lumefantrine following single oral and intravenous
Table 2 Pharmacokinetic parameters of lumefantrine after oral and intravenous administration in rats
Parameters Intravenous Per-oral
0.5 mg/kg 10 mg/kg 20 mg/kg 40 mg/kg
AUC0-t (hr*ng/mL) 9,189.76 ± 1,372.42 21,294.02 ± 3,235.75 17,683.7 ± 3,168.23 38,248.94 ± 7,792.61
AUC0-∞ (hr*ng/mL) 9,529.47 ± 1,283.18 22,025.48 ± 3,448.87 18,281.07 ± 3,062.84 39,958.71 ± 8,362.60
Cmax (ng/mL) 1,890 ± 330.61 1,488 ± 311.47 938.75 ± 370.64 2,280 ± 522.32
Tmax (hr) - 8(2-8) 3.5(2-8) 5(2-8)
Vd (L/kg) 2.40 ± 0.67 - - -
CL (L/h/kg) 0.03 ± 0.02 - - -
t1/2 (hr) 30.92 ± 4.81 36.08 ± 8.52 25.7 ± 1.85 38.23 ± 4.51
%F - 11.56 4.80 5.24
Figure 3 Plasma concentration versus time profiles of desbutyl-lumefantrine after oral and intravenous administration of lumefantrine
in rats (N = 4). All concentrations are on the logarithmic scale.
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mean oral and intravenous pharmacokinetic parameters
for desbutyl-lumefantrine are summarized in Table 3.
The desbutyl-lumefantrine was detected from 2 hr time
point, except at 40 mg/kg where it was detected from
first time point i.e. 0.05 hr. For nominal doses increasing
in a 1:2:4 proportion, the Cmax and AUC0-t values
increased in the proportions of 1:1.45:2.57 and
1:1.08:1.87, respectively. Following the intravenous
administration of lumefantrine, the Cmax and AUC0-t
value of desbutyl-lumefantrine was found to be 7.91 (±
1.89) ng/mL and 375.75 (± 74.26) ng.h/mL, respectively.
In conclusion, we successfully derived the pharmacoki-
netic parameters of lumefantrine and its metabolite des-
butyl-lumefantrine in rats for the first time.
Lumefantrine displayed similar pharmacokinetics in the
rat as in humans [14,18], with multiphasic disposition,
low clearance, and a large volume of distribution result-
ing in a long terminal elimination half-life.
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